🇺🇸 AUMOLERTINIB MESYLATE in United States

6 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 6

Most-reported reactions

1. Granulocyte Count Decreased — 1 report (16.67%)
2. Platelet Count Decreased — 1 report (16.67%)
3. Productive Cough — 1 report (16.67%)
4. Pyrexia — 1 report (16.67%)
5. Rhinorrhoea — 1 report (16.67%)
6. White Blood Cell Count Decreased — 1 report (16.67%)

Source database →

Frequently asked questions

Is AUMOLERTINIB MESYLATE approved in United States?

AUMOLERTINIB MESYLATE does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for AUMOLERTINIB MESYLATE in United States?

Marketing authorisation holder not available in our data.